JPMorgan Chase & Co. raised its holdings in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 1,898.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 199,725 shares of the specialty pharmaceutical company’s stock after buying an additional 189,730 shares during the quarter. JPMorgan Chase & Co. owned 0.72% of Paratek Pharmaceuticals worth $4,813,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Legal & General Group Plc increased its holdings in Paratek Pharmaceuticals by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after buying an additional 687 shares during the period. Fox Run Management L.L.C. bought a new stake in Paratek Pharmaceuticals in the 2nd quarter valued at $200,000. Russell Investments Group Ltd. bought a new stake in Paratek Pharmaceuticals in the 1st quarter valued at $211,000. American International Group Inc. increased its holdings in Paratek Pharmaceuticals by 34.1% in the 1st quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock valued at $214,000 after buying an additional 2,824 shares during the period. Finally, Appleton Partners Inc. MA bought a new stake in Paratek Pharmaceuticals in the 2nd quarter valued at $220,000. 82.37% of the stock is currently owned by hedge funds and other institutional investors.

PRTK has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, June 22nd. HC Wainwright boosted their price target on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a report on Tuesday, July 18th. BidaskClub lowered shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Saturday, August 5th. Finally, Raymond James Financial, Inc. reissued a “strong-buy” rating and issued a $36.00 price target on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. One analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $37.44.

TRADEMARK VIOLATION NOTICE: This piece was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/10/07/jpmorgan-chase-co-has-4-81-million-holdings-in-paratek-pharmaceuticals-inc-prtk.html.

Shares of Paratek Pharmaceuticals, Inc. (PRTK) opened at 25.40 on Friday. The company’s market cap is $705.13 million. The stock has a 50 day moving average of $25.04 and a 200 day moving average of $22.43. Paratek Pharmaceuticals, Inc. has a 12-month low of $9.80 and a 12-month high of $29.00.

Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million during the quarter, compared to the consensus estimate of $7.50 million.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.